Group One Trading’s Akebia Therapeutics AKBA Stock Holding History

Group One Trading’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$99.7K	Sell	71,700 -30,300	-30%	-$41.6K	﹤0.01%	4731
2025 Q4	$164K	Sell	102,000 -258,200	-72%	-$541K	﹤0.01%	4563
2025 Q3	$983K	Sell	360,200 -4,100	-1%	-$13.6K	﹤0.01%	3047
2025 Q2	$1.33M	Buy	364,300 +127,500	+54%	+$350K	﹤0.01%	2504
2025 Q1	$455K	Buy	236,800 +157,700	+199%	+$322K	﹤0.01%	3192
2024 Q4	$150K	Sell	79,100 -32,700	-29%	-$56.8K	﹤0.01%	4169
2024 Q3	$148K	Sell	111,800 -73,000	-40%	-$97.5K	﹤0.01%	3875
2024 Q2	$188K	Sell	184,800 -37,600	-17%	-$46.5K	﹤0.01%	3441
2024 Q1	$407K	Sell	222,400 -279,900	-56%	-$447K	﹤0.01%	2937
2023 Q4	$623K	Sell	502,300 -189,200	-27%	-$193K	﹤0.01%	2884
2023 Q3	$788K	Buy	691,500 +310,300	+81%	+$399K	﹤0.01%	2496
2023 Q2	$349K	Buy	381,200 +120,700	+46%	+$117K	﹤0.01%	3391
2023 Q1	$146K	Buy	260,500 +199,600	+328%	+$152K	﹤0.01%	3959
2022 Q4	$35.1K	Sell	60,900 -99,500	-62%	-$31.2K	﹤0.01%	5230
2022 Q3	$51K	Buy	160,400 +79,400	+98%	+$31.2K	﹤0.01%	5386
2022 Q2	$29K	Sell	81,000 -162,500	-67%	-$68.2K	﹤0.01%	5995
2022 Q1	$175K	Sell	243,500 -19,300	-7%	-$41.3K	﹤0.01%	4936
2021 Q4	$594K	Buy	262,800 +104,500	+66%	+$285K	﹤0.01%	3921
2021 Q3	$456K	Buy	158,300 +75,000	+90%	+$214K	﹤0.01%	4300
2021 Q2	$316K	Sell	83,300 -65,500	-44%	-$220K	﹤0.01%	4738
2021 Q1	$504K	Sell	148,800 -92,000	-38%	-$331K	﹤0.01%	4028
2020 Q4	$674K	Sell	240,800 -281,500	-54%	-$822K	﹤0.01%	3018
2020 Q3	$1.31M	Buy	522,300 +329,500	+171%	+$2.89M	﹤0.01%	1944
2020 Q2	$2.62M	Buy	192,800 +161,500	+516%	+$1.67M	0.01%	1268
2020 Q1	$237K	Sell	31,300 -47,200	-60%	-$367K	﹤0.01%	2620
2019 Q4	$496K	Buy	78,500 +78,000	+15,600%	+$371K	﹤0.01%	2439
2019 Q3	$2K	Sell	500 -1,500	-75%	-$6.43K	﹤0.01%	4899
2019 Q2	$10K	Sell	2,000 -5,000	-71%	-$28.4K	﹤0.01%	4409
2019 Q1	$57K	Sell	7,000 -32,900	-82%	-$226K	﹤0.01%	3488
2018 Q4	$221K	Buy	+39,900	New	+$312K	﹤0.01%	2606
2018 Q3	–	Sell	-1,400	Closed	-$14K	–	5137
2018 Q2	$14K	Sell	1,400 -23,900	-94%	-$239K	﹤0.01%	4502
2018 Q1	$241K	Buy	25,300 +14,800	+141%	+$207K	﹤0.01%	2636
2017 Q4	$156K	Buy	10,500 +10,200	+3,400%	+$169K	﹤0.01%	3088
2017 Q3	$6K	Sell	300 -34,900	-99%	-$537K	﹤0.01%	4417
2017 Q2	$506K	Buy	35,200 +4,800	+16%	+$60.8K	0.01%	1964
2017 Q1	$280K	Buy	30,400 +8,100	+36%	+$79.1K	﹤0.01%	2274
2016 Q4	$232K	Buy	22,300 +11,300	+103%	+$97.3K	﹤0.01%	2322
2016 Q3	$100K	Sell	11,000 -3,200	-23%	-$27.2K	﹤0.01%	2923
2016 Q2	$106K	Sell	14,200 -22,200	-61%	-$194K	﹤0.01%	2823
2016 Q1	$328K	Buy	36,400 +20,300	+126%	+$165K	﹤0.01%	1992
2015 Q4	$208K	Sell	16,100 -14,600	-48%	-$149K	﹤0.01%	2467
2015 Q3	$297K	Buy	30,700 +24,800	+420%	+$228K	﹤0.01%	2204
2015 Q2	$61K	Buy	5,900 +400	+7%	+$3.41K	﹤0.01%	3415
2015 Q1	$61K	Buy	5,500 +2,400	+77%	+$25.6K	﹤0.01%	3244
2014 Q4	$36K	Sell	3,100 -3,400	-52%	-$48.8K	﹤0.01%	3584
2014 Q3	$144K	Buy	+6,500	New	+$149K	﹤0.01%	2670

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Group One Trading's AKBA Position: Q1 2026 in Review

Group One Trading reduced its Akebia Therapeutics (AKBA) stake by 27% in Q1 2026, selling an estimated $48.6K and leaving 97,687 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #4442.

Group One Trading first reported a position in AKBA in Q3 2014 and has held it in 37 quarters since. The position peaked at $637K in Q1 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

Group One Trading held 97,687 shares of Akebia Therapeutics worth $136K as of Q1 2026.
Group One Trading sold 35,352 Akebia Therapeutics shares in Q1 2026, an estimated $48.6K.
Akebia Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #4442 holding.
Group One Trading first reported a position in Akebia Therapeutics in Q3 2014 and has held it in 37 quarters since.
Group One Trading's Akebia Therapeutics position peaked at $637K in Q1 2020.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.